|
GATAD2A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62436730732907E-12 |
| Normal-vs-Stage2 |
2.44920000003201E-06 |
| Normal-vs-Stage3 |
2.14184225910685E-12 |
| Normal-vs-Stage4 |
5.40678612992451E-14 |
| Stage1-vs-Stage2 |
6.697600E-01 |
| Stage1-vs-Stage3 |
9.914800E-01 |
| Stage1-vs-Stage4 |
1.337560E-01 |
| Stage2-vs-Stage3 |
7.073200E-01 |
| Stage2-vs-Stage4 |
1.472190E-01 |
| Stage3-vs-Stage4 |
1.777150E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
1.07969999996183E-06 |
| Normal-vs-Asian |
1.19519949492997E-11 |
| Caucasian-vs-AfricanAmerican |
1.204950E-01 |
| Caucasian-vs-Asian |
2.095600E-01 |
| AfricanAmerican-vs-Asian |
5.922400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.99200722162641E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
8.497400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
<1E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
3.53520546170216E-11 |
| Normal-vs-Age(81-100Yrs) |
1.67167999999274E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.380400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.167200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.504600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.464000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.805600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.019800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.874200E-01 |
| Classical-VS-Follicular |
4.00224298147123E-12 |
| Classical-VS-Other |
7.486500E-02 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
8.41980000000353E-05 |
| Tall-VS-Other |
8.754000E-02 |
| Tall-VS-Normal |
1.78180004084538E-09 |
| Follicular-VS-Other |
6.001400E-01 |
| Follicular-VS-Normal |
4.002900E-03 |
| Other-VS-Normal |
1.603620E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.72750702631674E-12 |
| Normal-vs-N1 |
5.03529995476981E-09 |
| N0-vs-N1 |
3.215200E-01 |
|
|
